The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
Other therapies hoping to provide a new way ... to the drug. And Cobenfy's approval comes after two other recent setbacks in the late-stage schizophrenia pipeline; namely, the FDA’s rejection ...
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for ...
Even if approved, TV-46000 could face a challenging time in the marketplace, as the market for long-acting injectables for schizophrenia – designed to improve patients' adherence with therapy ...
Magdalena aiming to submit Investigational New Drug ... psychoactive FDA-approved plant-based drugs under FDA Botanical Guidance for mental health indications including schizophrenia, anxiety ...
We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback